

Fu Yu Corporation Limited


Date: 20 May 2024

Non-rated

Date	20/5/2025	
BBG	FUYU SP	
Market Cap (S\$m)	96.9	
Price (S\$)	0.13	
52-week range (S\$)	0.12 - 0.20	
Target Price (S\$)	Non-rated	
Shares Outstanding (m)	762	
Free Float	68.80%	
Major Shareholder	Pilgrim Capital VCC	29.45%
P/BV (05/24)	0.7	
Net Debt to EBITDA (05/24)	-	

Source: Company data, Bloomberg, SAC Capital

1-Year Share Price



Source: Company data, Bloomberg, SAC Capital

Analyst June Yap +65 8833 1235 juneyap @saccapital.com.sg

Matthias Chan +65 9687 9957 mchan@saccapital.com.sg

1Q24 Turnaround Fuels Growth Trajectory

Fu Yu achieved a turnaround in 1Q24, reporting a net profit of \$\$5,200 compared to a net loss of \$\$2.4 m in 1Q23. One of its two business segments, the supply chain arm made a net profit of \$\$0.4m in 1Q24 and broke even in 1Q23. This implies its manufacturing business saw a significant y-y reduced loss of \$\$0.4 m in 1Q24 from a loss of \$\$2.4m in 1Q23.

The contrast between Fu Yu now and in the past is striking. Previously a dominant force, the company had experienced stagnation in capabilities and manpower over the last 10-15 years. Innovation and customer acquisition were slow, lacking excitement. However, with a new team on board and a newly-opened smart factory, the Group has revitalized its capabilities, enabling entry into new markets such as MedTech and IoT consumer electronics.

By recruiting skilled professionals from a prominent local precision plastics manufacturer, the Group has established a New Products Introduction (NPI) team. This team enables the Group to offer a comprehensive end-to-end service, seamlessly guiding products from the design stage through to mass production and market launch.

The four-level smart factory in Tuas, completed in December 2022, represents a significant advancement for Fu Yu. It boasts reduced yield loss, minimized human error, and enhanced precision levels, enabling the production of more intricate products. The factory has achieved products with precision levels of 2 to 5 microns, a substantial improvement from the previous 10 to 20 microns. Key features of this new facility include an automated tool room, considered one of the most advanced in precision manufacturing in Asia, and a sophisticated manufacturing execution system that provides real-time data to optimize efficiency and meet traceability requirements for customers.

The Group's strategic initiatives have borne fruit. Fu Yu was appointed as the exclusive contract manufacturer for Singapore's startup myFirst, facilitating myFirst's expansion into North America. Additionally, the Group secured two new projects with international partners: one for producing microfluidic chips for medical diagnostic devices and another for manufacturing high-precision tools for drug delivery devices. Furthermore, an MOU was signed in 1Q24 to be the exclusive plastics supplier for a Singapore-based medical device manufacturer, demonstrating the Group's commitment to expanding its presence in the MedTech industry.

Mr. David Seow, Group Chief Executive Officer of Fu Yu, expressed optimism about the Group's future growth trajectory, emphasizing the importance of expanding the project pipeline and executing strategic initiatives. Fu Yu aims to leverage its global supply chain to navigate challenges such as delayed shipments and rising costs, while continuing to target high-value projects in key sectors.

YE Dec (S\$m)	FY21A	FY22A	FY23A
Revenue	195.5	240.1	190.4
Net profit	17.6	14.6	(10.1)
EPS (S¢)	2.3	1.9	(1.3)
Dividend per share (S¢)	4.95	1.0	-
Dividend Payout (%)	211.5	52.6	-
Net cash / (debt)	Netcash	Netcash	Netcash
Valuation			
Gross profit margin (%)	18.6	15.7	7.0
Net profit margin (%)	9.0	6.1	-
P/E (x)	5.5	6.6	-
Р/В (х)	0.6	0.6	0.7



Fu Yu is headquartered in Singapore



Fu Yu Corporation Limited (Headquarters)

No 9, Tuas Drive 1, Singapore 638676

2 manufacturing sites in Malaysia

3 manufacturing

sites in China



Classic Advantage Sdn Bhd

No. 21, Jalan Teknologi 4, Taman Teknologi 81400 Senai, Johor, Malaysia



Fu Hao Manufacturing Sdn Bhd

Plot 562, Mukim 1, Jalan Perusahaan Baru 1 Perai III, Perai Industrial Estate 13600 Perai, Penang, Malaysia



Fu Yu Moulding & Tooling (Suzhou) Co., Ltd

No. 89, Xing Nan Road Wu Zhong Economic Development Zone Suzhou, Jiangsu China 215128



Fu Yu Moulding & Tooling (Dongguan) Co., Ltd

Jing Fu Road, Xin Cheng Industry Area Heng Li Town, Dongguan Guangdong China 523477



Fu Yu Moulding & Tooling (Zhuhai) Co., Ltd

477 Jin Hai An Avenue Sanzao, Jinwan district Zhuhai, Guangdong China 519040

Fu Yu began mass production in April 2024 for a S\$15m contract with myFirst



Fu Yu group chief executive and executive director David Seow (left) and myFirst co-founder and chief executive G-Jay Yong, PHOTO: FU YU



Fu Yu has the capabilities to meet the precise manufacturing specifications required by potential customers in the Medtech sector.







Fu Yu manufactures Consumer products across various categories.



Income Statement			
YE Dec (S\$m)	FY21A	FY22A	FY23A
Revenue	195.5	240.1	190.4
Cost of sales	(159.1)	(202.5)	(177.1)
Gross profit	36.5	37.6	13.3
Gross profit margin	19%	16%	7%
Other income	3.3	2.5	3.7
Selling and administrative expenses	(19.5)	(22.9)	(23.5)
Other operating income, net	1.2	0.6	(3.2)
Results from operating activities	21.5	17.8	(9.6)
Finance costs	(0.3)	(0.4)	(0.9)
Profit before tax	21.2	17.4	(10.6)
Tax expense	(3.7)	(2.8)	0.5
Net profit	17.6	14.6	(10.1)
Net profit margin	9%	6%	-5%

Balance Sheet

YE Dec (S\$m)	FY21A	FY22A	FY23A
Non-current assets	11214	11228	TIZOA
Property, plant and equipment	60.0	63.0	58.2
Investment property	7.4	6.1	5.7
Subsidiaries	-	-	-
Goodwill	6.0	6.0	3.2
Other receivables	-	-	-
Deferred tax assets	1.0	0.8	1.3
Total non-current assets	74.4	75.9	68.3
Current assets			
Inventories	17.1	18.4	13.4
Contract assets	1.7	1.6	1.9
Trade and other receivables	35.7	31.9	31.4
Tax recoverable	-	-	0.9
Cash and bank balances	83.9	79.3	60.3
Total current assets	138.5	131.2	107.9
Total assets	212.9	207.2	176.2
Equity attributable to equity holders			
of the Company			
Share capital	102.2	102.2	103.0
Reserves	51.7	53.0	34.5
Total equity	153.9	155.2	137.4
Non-current liabilities			
Trade and other payables	0.3	0.4	1.1
Loans and borrowings	9.4	9.1	5.0
Deferred tax liabilities	1.7	1.8	1.7
Total non-current liabilities	11.4	11.3	7.9
Current liabilities			
Trade and other payables	35.2	32.4	24.9
Contract liabilities	0.6	0.8	0.5
Loans and borrowings	4.0	5.0	4.2
Tax payable	7.8	2.5	1.2
Total current liabilities	47.6	40.7	30.9
Total liabilities	59.0	52.0	38.7
Total equity and liabilities	212.9	207.2	176.2

Cash Flow Statement

YE Dec (S\$m)	FY21A	FY22A	FY23A
Cash flows from operating activities			(10.0)
Profit before income tax	21.2	17.4	(10.6)
Adjustments for:			
Depreciation of PPE & invt prop	7.8	7.8	8.6
Loss on liquidation of a subsidiary	0.1	0.3	0.4
Finance costs	0.3	0.4	0.9
Interest income	(0.5)	(0.8)	(1.9)
Gain on disposal of PPE	(0.7)	(0.1)	-
Provision of impairment on goodwill	-	-	2.7
Equity-settled share-based payment		0.0	4.0
transactions	-	0.9	1.3
Unrealised foreign exchange	(0,0)		
(gain)/loss	(0.6)	1.2	0.7
	27.7	26.9	2.1
Changes in working capital:	(0,0)	(0, 1)	
Inventories	(3.6)	(2.4)	4.4
Trade and other receivables	6.2	2.0	(0.4)
Contract assets	-	-	(0.3)
Trade and other payables	(4.3)	1.9	(7.3)
Contract liabilities	0.2	0.3	(0.2)
Cash generated from operating	00.0	00 7	(4.0)
activities	26.2	28.7	(1.8)
Tax paid	(3.5)	(6.9)	(2.7)
Net cash generated from operating	00.7	04 7	
activities	22.7	21.7	(4.5)
Cash flows from investing activities Acquisition of subsidiary, net of cash	(1.0)		
Interest income received	(1.8) 0.5	0.8	1.9
Proceeds from disposal of PPE	0.5	0.8	1.5
Purchase of PPE	(13.2)	(11.6)	- (4.0)
	(13.2)	(11.0)	(4.0)
Net cash used in investing activities	(13.6)	(10.6)	(2.1)
Cash flows from financing activities			
Repayment of lease liabilities	(1.1)	(1.3)	(1.3)
Repayment of unsecured bank loan	-	(2.7)	(4.0)
Proceeds from unsecured bank loans	5.7	4.3	-
Finance costs paid	-	(0.3)	(0.5)
Dividends paid to owners of the			
Company	(37.3)	(12.4)	(4.5)
Deposits pledged	-	-	-
Cash restricted-in-use	(10.1)	1.7	2.5
Net cash used in financing activities	(42.8)	(10.7)	(7.9)
Net increase/(decrease) in cash and	(12.0)	(2007)	().0)
cash equivalents	(33.7)	0.4	(14.4)
Cash and cash equivalents at 1	(***)		. ,
January	106.5	73.8	71.4
Effect of exchange rate fluctuations			
on cash held	1.0	(2.8)	(1.8)
Cash and cash equivalents at 31	1.0	()	(1.0)
December	73.8	71.4	55.2



DISCLAIMERS AND DISCLOSURES

This report has been prepared and distributed by SAC Capital Private Limited ("**SAC Capital**") which is a holder of a capital markets services licence and an exempt financial adviser in Singapore.

This report has been prepared for the purpose of general circulation, we have not had regard to the specific investment objectives, financial situation, tax position or unique needs and constraints of any individual person or any specific group of persons and does not purport to be comprehensive or contain all necessary information which a prospective investor may require in arriving at an investment decision. Any prospective purchaser should make his own investigation of the securities and all information provided. Advice should be sought from a financial adviser regarding suitability, taking into account the specific investment objectives, financial situation or particular needs of the person in receipt of the recommendation, before a commitment to purchase is entered into.

This report does not constitute or form part of any offer or solicitation of any offer to buy or sell any securities. This report is confidential and the information in this report shall not be copied or reproduced in part or in whole, and save for the recipient of this report, shall not be disclosed to any other person without the prior written consent of SAC Capital. The distribution of this report outside the jurisdiction of Singapore is also strictly prohibited.

Whereas SAC Capital has not independently verified all the information set out in this report, all reasonable care and effort has been taken to ensure that the facts stated herein are accurate, this report might contain certain forward looking statements and forward looking financial information which are based on certain assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results or performance of the subject company to be materially different from those expressed herein. Predictions, projections or forecasts of the economy or market trends are not indicative of the future performance of the subject company. The inclusion of such statements and information should not be regarded as a representation, warranty or prediction with respect to the accuracy of the underlying assumptions of the subject company or that the forecast results will or are likely to be achieved.

Our opinion and facts set out in this report are based on the market, economic, industry and other applicable conditions prevailing as at the date of the preparation of this report. Such conditions may change significantly over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report, that may or may not have affected our opinion contained herein.

This report contains forward-looking statement which are based on assumptions or forecasts and are subject to uncertainties which may result in the actual result or performance to be materially different from the opinion or facts set out herein. Caution should be exercised in placing undue reliance on such statements. such assumptions or forecasts may change over a relatively short period of time and we assume no responsibility to update, revise or reaffirm our opinion in light of any development subsequent to the publication of this report.

No representation or warranty, expressed or implied, is made and no responsibility is accepted by the company, SAC Capital, or any of their affiliates, advisers or representatives as to the fairness, accuracy, completeness or adequacy of such information or facts, in this report or any other written or oral information made available to any interested party or its advisers and any liability therefore is hereby expressly disclaimed.

SAC Capital and its associates, directors, and/or employees may have positions in the securities covered in the report and may also perform or seek to perform other corporate finance and/or capital markets related services for the company whose securities are covered in the report. SAC Capital and its related companies may from time to time perform advisory services or solicit such advisory services from the entity mentioned in this report ("**Other Services**"). This report is therefore classified as a non-independent report. However, the research professionals involved in the preparation of this report are independent of those possible or actual business relationships as they have not and will not participate in the solicitation or provision of such business.

As at the date of this report, SAC Capital does not have proprietary positions or interests in the subject company, except for:

Party	Quantum of position
Nil	Nil

For services rendered in the production and distribution of this Research report, SAC Capital will receive monetary compensation payable by the subject company. The quantum of which was pre-determined prior to the writing and publication of the report and is not dependent on or affected by the recommendation made herein. The future performance of the security will not have a bearing on compensation payable for the purpose of the production of this report.



As at the date of this report, none of the analysts who covered the securities in this report have any proprietary position or material interest in the subject companies covered here in, except for:

Analyst name	Quantum of position
Nil	Nil

ANALYST CERTIFICATION/REGULATION AC

As noted above, research analyst(s) of SAC Capital who produced this report hereby certify that

(i) The views expressed in this report accurately reflect his/her personal views about the subject corporation(s);

(ii) The report was produced independently by him/her;

(iii) He/she does not on behalf of SAC Capital or any other person carry out Other Services involving any of the subject corporation(s) or securities referred to in this report; and

(iv) He/she has not received and will not receive any compensation directly or indirectly related to the recommendations or views expressed in this report or to any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. He/she has not and will not receive any compensation directly or indirectly linked to the performance of the securities of the subject corporation(s) from the time of the publication of this report either.